Advanced breast cancer

The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


Triple-negative breast cancer ( TNBC ) is an aggressive subtype of breast cancer, often resistant to standard of care therapies....


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...



The FDA ( Food and Drug Administration ) has granted full approval for Tagrisso ( Osimertinib ) 80mg once-daily tablets,...


Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system...


Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune...


Palbociclib ( Ibrance ) is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2...


The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer...


The FDA ( Food and Drug Administration ) has granted accelerated approval for Keytruda ( Pembrolizumab ) to treat patients...


Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A )...


Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [...


The European Commission has approved Humira ( Adalimumab ) for the treatment of active moderate to severe hidradenitis suppurativa...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF...



A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated...


The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Ibrance ( Palbociclib ) to treat advanced...